BG
BBOT

Bellevue Group’s BridgeBio Oncology BBOT Stock Holding History

Bellevue Group’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62.5K Buy
+6,982
New +$75K ﹤0.01% 147

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group's BBOT Position: Q1 2026 in Review

Bellevue Group opened a new position in BridgeBio Oncology (BBOT) in Q1 2026: 6,982 shares worth $62.5K. The stake represents ﹤0.01% of the portfolio and ranks #147 among its holdings.

67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Bellevue Group held 6,982 shares of BridgeBio Oncology worth $62.5K as of Q1 2026.
  • BridgeBio Oncology was a new Bellevue Group position in Q1 2026.
  • BridgeBio Oncology made up ﹤0.01% of Bellevue Group's portfolio in Q1 2026, its #147 holding.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.